DTIL
HealthcarePrecision BioSciences, Inc.
$5.63-0.04 (-0.79%)
Prev Close
$5.67
Open
$5.77
High
$6.05
Low
$5.40
Volume
246.5K
Market Cap
$62.4M
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Precision BioSciences, Inc. (DTIL) has been dominated by selling, with 10 insider purchases totaling $129.1K and 17 insider sales totaling $682.8K. The most recent insider transaction was by Amoroso Michael (director, officer: President and CEO), who sold $78.9K worth of shares on Feb 19, 2026. Precision BioSciences, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $62.4M.
Buys (12M)
10
$129.1K
Sells (12M)
17
$682.8K
Net Activity
Net Seller
$553.6K
Active Insiders
8
last 12 mo
DTIL Price Chart
DTIL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 19, 2026↗ | Amoroso Michael | director, officer: President and CEO | Sell | 20,559 | $3.84 | $78.9K | 243,392 |
| Feb 19, 2026↗ | Kelly John Alexander | officer: Chief Financial Officer | Sell | 8,149 | $3.84 | $31.3K | 125,883 |
| Feb 19, 2026↗ | Scimeca Dario | officer: General Counsel and Secretary | Sell | 4,925 | $3.84 | $18.9K | 56,457 |
| Feb 19, 2026↗ | SMITH J. JEFFERSON | officer: Chief Research Officer | Sell | 4,925 | $3.84 | $18.9K | 121,926 |
| Feb 17, 2026↗ | Amoroso Michael | President and CEO | Sell | 20,559 | $3.84 | $78.9K | 0 |
| Feb 17, 2026↗ | Kelly John Alexander | Chief Financial Officer | Sell | 8,149 | $3.84 | $31.3K | 0 |
| Feb 17, 2026↗ | Scimeca Dario | General Counsel and Secretary | Sell | 4,925 | $3.84 | $18.9K | 0 |
| Feb 17, 2026↗ | SMITH J. JEFFERSON | Chief Research Officer | Sell | 4,925 | $3.84 | $18.9K | 0 |
| Jan 22, 2026↗ | Amoroso Michael | director, officer: President and CEO | Sell | 34,799 | $4.17 | $145.1K | 196,154 |
| Jan 22, 2026↗ | Kelly John Alexander | officer: Chief Financial Officer | Sell | 15,213 | $4.03 | $61.3K | 106,448 |
| Jan 22, 2026↗ | Scimeca Dario | officer: General Counsel and Secretary | Sell | 8,854 | $4.03 | $35.7K | 44,715 |
| Jan 22, 2026↗ | SMITH J. JEFFERSON | officer: Chief Research Officer | Sell | 10,200 | $4.03 | $41.1K | 110,184 |
| Dec 17, 2025↗ | Brown Melinda | Director | Buy | 1,381 | $4.97 | $6.9K | 23,346 |
| Dec 17, 2025↗ | Frankel Stanley | Director | Buy | 2,700 | $4.70 | $12.7K | 19,478 |
| Dec 17, 2025↗ | Germano Geno J | Director | Buy | 3,000 | $4.72 | $14.2K | 23,883 |
| Nov 4, 2025↗ | Amoroso Michael | President and CEO | Sell | 3,409 | $6.49 | $22.1K | 115,575 |
| Nov 4, 2025↗ | Kelly John Alexander | Chief Financial Officer | Sell | 1,303 | $6.49 | $8.5K | 77,298 |
| Nov 4, 2025↗ | Scimeca Dario | General Counsel and Secretary | Sell | 665 | $6.49 | $4.3K | 28,258 |
| Sep 30, 2025↗ | Frankel Stanley | Director | Buy | 2,700 | $4.97 | $13.4K | 16,778 |
| Sep 24, 2025↗ | Brown Melinda | Director | Buy | 1,400 | $4.89 | $6.8K | 21,965 |
| Jul 8, 2025↗ | Kelly John Alexander | Chief Financial Officer | Sell | 14,827 | $4.26 | $63.2K | 73,485 |
| Jun 27, 2025↗ | Brown Melinda | Director | Buy | 1,682 | $4.14 | $7.0K | 20,565 |
| Jun 27, 2025↗ | Buehler Kevin | Director | Buy | 5,076 | $4.16 | $21.1K | 28,137 |
| Mar 28, 2025↗ | Brown Melinda | Buy | 1,839 | $4.75 | $8.7K | 9,057 | |
| Mar 28, 2025↗ | Buehler Kevin | Buy | 4,523 | $4.67 | $21.1K | 13,235 | |
| Mar 27, 2025↗ | Germano Geno J | Buy | 3,250 | $5.30 | $17.2K | 11,057 | |
| Mar 25, 2025↗ | Amoroso Michael | President and CEO | Sell | 964 | $5.56 | $5.4K | 109,540 |
| Mar 5, 2025↗ | Scimeca Dario | General Counsel and Secretary | Sell | 272 | $4.91 | $1.3K | 25,000 |
| Mar 5, 2025↗ | SMITH J. JEFFERSON | Chief Research Officer | Sell | 154 | $4.91 | $756.14 | 87,805 |
| Jan 22, 2025↗ | Amoroso Michael | President and CEO | Sell | 36,838 | $4.67 | $172.0K | 107,087 |
| Jan 22, 2025↗ | Scimeca Dario | General Counsel and Secretary | Sell | 8,928 | $4.79 | $42.8K | 24,353 |
| Jan 22, 2025↗ | SMITH J. JEFFERSON | Chief Research Officer | Sell | 10,287 | $4.79 | $49.3K | 87,440 |
| Jan 2, 2025↗ | Germano Geno J | Buy | 3,605 | $4.49 | $16.2K | 7,807 | |
| Dec 31, 2024↗ | Buehler Kevin | Buy | 4,320 | $4.88 | $21.1K | 8,712 | |
| Dec 31, 2024↗ | Kelly John Alexander | Chief Financial Officer | Buy | 2,113 | $4.75 | $10.0K | 40,186 |
| Dec 30, 2024↗ | Brown Melinda | Buy | 3,016 | $4.55 | $13.7K | 7,218 | |
| Nov 21, 2024↗ | Kelly John Alexander | Chief Financial Officer | Buy | 3,000 | $6.76 | $20.3K | 38,073 |
| Nov 5, 2024↗ | Amoroso Michael | President and CEO | Sell | 3,012 | $8.19 | $24.7K | 28,537 |
| Nov 5, 2024↗ | Scimeca Dario | General Counsel and Secretary | Sell | 588 | $8.19 | $4.8K | 7,969 |
| Jun 11, 2024↗ | Scimeca Dario | General Counsel and Secretary | Sell | 93 | $11.79 | $1.1K | 6,721 |
| Jun 11, 2024↗ | SMITH J. JEFFERSON | Chief Research Officer | Sell | 50 | $11.79 | $589.50 | 68,559 |
| May 3, 2024↗ | Amoroso Michael | President and CEO | Sell | 1,526 | $10.32 | $15.7K | 13,772 |
| May 3, 2024↗ | List Alan | Chief Medical Officer | Sell | 290 | $10.32 | $3.0K | 4,488 |
| May 3, 2024↗ | Scimeca Dario | General Counsel and Secretary | Sell | 272 | $10.32 | $2.8K | 5,680 |
| May 3, 2024↗ | SMITH J. JEFFERSON | Chief Research Officer | Sell | 154 | $10.32 | $1.6K | 67,613 |
| Apr 30, 2024↗ | List Alan | Chief Medical Officer | Sell | 238 | $10.03 | $2.4K | 3,796 |
| Jan 23, 2024↗ | Amoroso Michael | President and CEO | Sell | 137,390 | $0.36 | $49.5K | 356,433 |
| Jan 23, 2024↗ | List Alan | Chief Medical Officer | Sell | 21,526 | $0.36 | $7.7K | 94,982 |
| Jan 23, 2024↗ | Scimeca Dario | General Counsel and Secretary | Sell | 21,287 | $0.36 | $7.7K | 151,028 |
| Jan 23, 2024↗ | SMITH J. JEFFERSON | Chief Research Officer | Sell | 28,000 | $0.37 | $10.4K | 1,987,270 |
| Nov 6, 2023↗ | Amoroso Michael | President and CEO | Sell | 125,025 | $0.40 | $50.0K | 227,103 |
| Nov 6, 2023↗ | Scimeca Dario | General Counsel and Secretary | Sell | 16,023 | $0.40 | $6.4K | 112,970 |
| Jun 9, 2023↗ | Scimeca Dario | General Counsel and Secretary | Sell | 13,361 | $0.75 | $10.0K | 68,473 |
| Apr 28, 2023↗ | List Alan | Chief Medical Officer | Sell | 7,771 | $0.79 | $6.1K | 56,496 |
| Mar 23, 2023↗ | Amoroso Michael | President and CEO | Sell | 46,999 | $0.82 | $38.5K | 68,738 |
| Mar 21, 2023↗ | Kelly John Alexander | Chief Financial Officer | Buy | 20,000 | $0.86 | $17.2K | 245,614 |
| Mar 7, 2023↗ | List Alan | Chief Medical Officer | Sell | 9,473 | $1.07 | $10.1K | 38,240 |
| Mar 7, 2023↗ | Scimeca Dario | General Counsel and Secretary | Sell | 12,172 | $1.07 | $13.0K | 50,063 |
| Oct 18, 2022↗ | Amoroso Michael | President and CEO | Sell | 11,006 | $1.32 | $14.5K | 13,202 |
| Sep 26, 2022↗ | Kelly John Alexander | Chief Financial Officer | Buy | 45,237 | $1.32 | $59.7K | 162,938 |
| Jun 24, 2022↗ | Kelly John Alexander | Chief Financial Officer | Buy | 33,784 | $1.50 | $50.7K | 117,701 |
| Jun 9, 2022↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 18,849 | $2.06 | $38.8K | 4,055,170 |
| Jun 9, 2022↗ | Scimeca Dario | General Counsel and Secretary | Sell | 9,833 | $2.06 | $20.3K | 32,514 |
| Apr 28, 2022↗ | List Alan | Chief Medical Officer | Sell | 7,775 | $2.10 | $16.3K | 18,260 |
| Mar 21, 2022↗ | Kelly John Alexander | Chief Financial Officer | Buy | 16,677 | $3.08 | $51.4K | 36,189 |
| Jun 25, 2021↗ | THOMSON DAVID S. | Chief Operating Officer | Sell | 30,000 | $10.65 | $319.5K | 111,513 |
| Jun 23, 2021↗ | THOMSON DAVID S. | Chief Operating Officer | Sell | 15,000 | $10.77 | $161.6K | 111,513 |
| Jun 21, 2021↗ | THOMSON DAVID S. | Chief Operating Officer | Sell | 20,000 | $10.72 | $214.4K | 111,513 |
| Jun 16, 2021↗ | THOMSON DAVID S. | Chief Operating Officer | Sell | 2,858 | $11.20 | $32.0K | 111,513 |
| Jun 15, 2021↗ | THOMSON DAVID S. | Chief Operating Officer | Sell | 30,000 | $11.52 | $345.6K | 111,513 |
| May 19, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 20,000 | $9.38 | $187.6K | 4,032,280 |
| May 18, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 9,673 | $9.17 | $88.7K | 4,052,280 |
| May 14, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 19,349 | $8.93 | $172.9K | 4,040,440 |
| May 14, 2021↗ | KANE MATTHEW R. | President and CEO | Sell | 9,675 | $8.96 | $86.7K | 2,013,600 |
| May 11, 2021↗ | KANE MATTHEW R. | President and CEO | Sell | 19,488 | $8.41 | $163.9K | 2,001,760 |
| Apr 21, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 9,676 | $8.69 | $84.1K | 4,016,760 |
| Apr 19, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 19,351 | $8.80 | $170.3K | 4,004,920 |
| Apr 14, 2021↗ | KANE MATTHEW R. | President and CEO | Sell | 9,741 | $8.67 | $84.5K | 1,964,800 |
| Apr 12, 2021↗ | KANE MATTHEW R. | President and CEO | Sell | 19,473 | $8.93 | $174.0K | 1,953,020 |
| Mar 22, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 9,665 | $11.08 | $107.1K | 3,981,240 |
| Mar 18, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 19,326 | $11.44 | $221.2K | 3,969,400 |
| Mar 16, 2021↗ | KANE MATTHEW R. | President and CEO | Sell | 9,712 | $11.36 | $110.3K | 1,929,470 |
| Mar 12, 2021↗ | KANE MATTHEW R. | President and CEO | Sell | 19,421 | $11.58 | $225.0K | 1,917,670 |
DTIL Insider Buying Activity
The following table shows recent insider purchases of Precision BioSciences, Inc. (DTIL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Dec 17, 2025↗ | Brown Melinda | Director | Buy | 1,381 | $4.97 | $6.9K | 23,346 |
| Dec 17, 2025↗ | Frankel Stanley | Director | Buy | 2,700 | $4.70 | $12.7K | 19,478 |
| Dec 17, 2025↗ | Germano Geno J | Director | Buy | 3,000 | $4.72 | $14.2K | 23,883 |
| Sep 30, 2025↗ | Frankel Stanley | Director | Buy | 2,700 | $4.97 | $13.4K | 16,778 |
| Sep 24, 2025↗ | Brown Melinda | Director | Buy | 1,400 | $4.89 | $6.8K | 21,965 |
| Jun 27, 2025↗ | Brown Melinda | Director | Buy | 1,682 | $4.14 | $7.0K | 20,565 |
| Jun 27, 2025↗ | Buehler Kevin | Director | Buy | 5,076 | $4.16 | $21.1K | 28,137 |
| Mar 28, 2025↗ | Brown Melinda | Buy | 1,839 | $4.75 | $8.7K | 9,057 | |
| Mar 28, 2025↗ | Buehler Kevin | Buy | 4,523 | $4.67 | $21.1K | 13,235 | |
| Mar 27, 2025↗ | Germano Geno J | Buy | 3,250 | $5.30 | $17.2K | 11,057 | |
| Jan 2, 2025↗ | Germano Geno J | Buy | 3,605 | $4.49 | $16.2K | 7,807 | |
| Dec 31, 2024↗ | Buehler Kevin | Buy | 4,320 | $4.88 | $21.1K | 8,712 | |
| Dec 31, 2024↗ | Kelly John Alexander | Chief Financial Officer | Buy | 2,113 | $4.75 | $10.0K | 40,186 |
| Dec 30, 2024↗ | Brown Melinda | Buy | 3,016 | $4.55 | $13.7K | 7,218 | |
| Nov 21, 2024↗ | Kelly John Alexander | Chief Financial Officer | Buy | 3,000 | $6.76 | $20.3K | 38,073 |
| Mar 21, 2023↗ | Kelly John Alexander | Chief Financial Officer | Buy | 20,000 | $0.86 | $17.2K | 245,614 |
| Sep 26, 2022↗ | Kelly John Alexander | Chief Financial Officer | Buy | 45,237 | $1.32 | $59.7K | 162,938 |
| Jun 24, 2022↗ | Kelly John Alexander | Chief Financial Officer | Buy | 33,784 | $1.50 | $50.7K | 117,701 |
| Mar 21, 2022↗ | Kelly John Alexander | Chief Financial Officer | Buy | 16,677 | $3.08 | $51.4K | 36,189 |
DTIL Insider Selling Activity
The following table shows recent insider sales of Precision BioSciences, Inc. (DTIL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 19, 2026↗ | Amoroso Michael | director, officer: President and CEO | Sell | 20,559 | $3.84 | $78.9K | 243,392 |
| Feb 19, 2026↗ | Kelly John Alexander | officer: Chief Financial Officer | Sell | 8,149 | $3.84 | $31.3K | 125,883 |
| Feb 19, 2026↗ | Scimeca Dario | officer: General Counsel and Secretary | Sell | 4,925 | $3.84 | $18.9K | 56,457 |
| Feb 19, 2026↗ | SMITH J. JEFFERSON | officer: Chief Research Officer | Sell | 4,925 | $3.84 | $18.9K | 121,926 |
| Feb 17, 2026↗ | Amoroso Michael | President and CEO | Sell | 20,559 | $3.84 | $78.9K | 0 |
| Feb 17, 2026↗ | Kelly John Alexander | Chief Financial Officer | Sell | 8,149 | $3.84 | $31.3K | 0 |
| Feb 17, 2026↗ | Scimeca Dario | General Counsel and Secretary | Sell | 4,925 | $3.84 | $18.9K | 0 |
| Feb 17, 2026↗ | SMITH J. JEFFERSON | Chief Research Officer | Sell | 4,925 | $3.84 | $18.9K | 0 |
| Jan 22, 2026↗ | Amoroso Michael | director, officer: President and CEO | Sell | 34,799 | $4.17 | $145.1K | 196,154 |
| Jan 22, 2026↗ | Kelly John Alexander | officer: Chief Financial Officer | Sell | 15,213 | $4.03 | $61.3K | 106,448 |
| Jan 22, 2026↗ | Scimeca Dario | officer: General Counsel and Secretary | Sell | 8,854 | $4.03 | $35.7K | 44,715 |
| Jan 22, 2026↗ | SMITH J. JEFFERSON | officer: Chief Research Officer | Sell | 10,200 | $4.03 | $41.1K | 110,184 |
| Nov 4, 2025↗ | Amoroso Michael | President and CEO | Sell | 3,409 | $6.49 | $22.1K | 115,575 |
| Nov 4, 2025↗ | Kelly John Alexander | Chief Financial Officer | Sell | 1,303 | $6.49 | $8.5K | 77,298 |
| Nov 4, 2025↗ | Scimeca Dario | General Counsel and Secretary | Sell | 665 | $6.49 | $4.3K | 28,258 |
| Jul 8, 2025↗ | Kelly John Alexander | Chief Financial Officer | Sell | 14,827 | $4.26 | $63.2K | 73,485 |
| Mar 25, 2025↗ | Amoroso Michael | President and CEO | Sell | 964 | $5.56 | $5.4K | 109,540 |
| Mar 5, 2025↗ | Scimeca Dario | General Counsel and Secretary | Sell | 272 | $4.91 | $1.3K | 25,000 |
| Mar 5, 2025↗ | SMITH J. JEFFERSON | Chief Research Officer | Sell | 154 | $4.91 | $756.14 | 87,805 |
| Jan 22, 2025↗ | Amoroso Michael | President and CEO | Sell | 36,838 | $4.67 | $172.0K | 107,087 |
| Jan 22, 2025↗ | Scimeca Dario | General Counsel and Secretary | Sell | 8,928 | $4.79 | $42.8K | 24,353 |
| Jan 22, 2025↗ | SMITH J. JEFFERSON | Chief Research Officer | Sell | 10,287 | $4.79 | $49.3K | 87,440 |
| Nov 5, 2024↗ | Amoroso Michael | President and CEO | Sell | 3,012 | $8.19 | $24.7K | 28,537 |
| Nov 5, 2024↗ | Scimeca Dario | General Counsel and Secretary | Sell | 588 | $8.19 | $4.8K | 7,969 |
| Jun 11, 2024↗ | Scimeca Dario | General Counsel and Secretary | Sell | 93 | $11.79 | $1.1K | 6,721 |
| Jun 11, 2024↗ | SMITH J. JEFFERSON | Chief Research Officer | Sell | 50 | $11.79 | $589.50 | 68,559 |
| May 3, 2024↗ | Amoroso Michael | President and CEO | Sell | 1,526 | $10.32 | $15.7K | 13,772 |
| May 3, 2024↗ | List Alan | Chief Medical Officer | Sell | 290 | $10.32 | $3.0K | 4,488 |
| May 3, 2024↗ | Scimeca Dario | General Counsel and Secretary | Sell | 272 | $10.32 | $2.8K | 5,680 |
| May 3, 2024↗ | SMITH J. JEFFERSON | Chief Research Officer | Sell | 154 | $10.32 | $1.6K | 67,613 |
| Apr 30, 2024↗ | List Alan | Chief Medical Officer | Sell | 238 | $10.03 | $2.4K | 3,796 |
| Jan 23, 2024↗ | Amoroso Michael | President and CEO | Sell | 137,390 | $0.36 | $49.5K | 356,433 |
| Jan 23, 2024↗ | List Alan | Chief Medical Officer | Sell | 21,526 | $0.36 | $7.7K | 94,982 |
| Jan 23, 2024↗ | Scimeca Dario | General Counsel and Secretary | Sell | 21,287 | $0.36 | $7.7K | 151,028 |
| Jan 23, 2024↗ | SMITH J. JEFFERSON | Chief Research Officer | Sell | 28,000 | $0.37 | $10.4K | 1,987,270 |
| Nov 6, 2023↗ | Amoroso Michael | President and CEO | Sell | 125,025 | $0.40 | $50.0K | 227,103 |
| Nov 6, 2023↗ | Scimeca Dario | General Counsel and Secretary | Sell | 16,023 | $0.40 | $6.4K | 112,970 |
| Jun 9, 2023↗ | Scimeca Dario | General Counsel and Secretary | Sell | 13,361 | $0.75 | $10.0K | 68,473 |
| Apr 28, 2023↗ | List Alan | Chief Medical Officer | Sell | 7,771 | $0.79 | $6.1K | 56,496 |
| Mar 23, 2023↗ | Amoroso Michael | President and CEO | Sell | 46,999 | $0.82 | $38.5K | 68,738 |
| Mar 7, 2023↗ | List Alan | Chief Medical Officer | Sell | 9,473 | $1.07 | $10.1K | 38,240 |
| Mar 7, 2023↗ | Scimeca Dario | General Counsel and Secretary | Sell | 12,172 | $1.07 | $13.0K | 50,063 |
| Oct 18, 2022↗ | Amoroso Michael | President and CEO | Sell | 11,006 | $1.32 | $14.5K | 13,202 |
| Jun 9, 2022↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 18,849 | $2.06 | $38.8K | 4,055,170 |
| Jun 9, 2022↗ | Scimeca Dario | General Counsel and Secretary | Sell | 9,833 | $2.06 | $20.3K | 32,514 |
| Apr 28, 2022↗ | List Alan | Chief Medical Officer | Sell | 7,775 | $2.10 | $16.3K | 18,260 |
| Jun 25, 2021↗ | THOMSON DAVID S. | Chief Operating Officer | Sell | 30,000 | $10.65 | $319.5K | 111,513 |
| Jun 23, 2021↗ | THOMSON DAVID S. | Chief Operating Officer | Sell | 15,000 | $10.77 | $161.6K | 111,513 |
| Jun 21, 2021↗ | THOMSON DAVID S. | Chief Operating Officer | Sell | 20,000 | $10.72 | $214.4K | 111,513 |
| Jun 16, 2021↗ | THOMSON DAVID S. | Chief Operating Officer | Sell | 2,858 | $11.20 | $32.0K | 111,513 |
| Jun 15, 2021↗ | THOMSON DAVID S. | Chief Operating Officer | Sell | 30,000 | $11.52 | $345.6K | 111,513 |
| May 19, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 20,000 | $9.38 | $187.6K | 4,032,280 |
| May 18, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 9,673 | $9.17 | $88.7K | 4,052,280 |
| May 14, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 19,349 | $8.93 | $172.9K | 4,040,440 |
| May 14, 2021↗ | KANE MATTHEW R. | President and CEO | Sell | 9,675 | $8.96 | $86.7K | 2,013,600 |
| May 11, 2021↗ | KANE MATTHEW R. | President and CEO | Sell | 19,488 | $8.41 | $163.9K | 2,001,760 |
| Apr 21, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 9,676 | $8.69 | $84.1K | 4,016,760 |
| Apr 19, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 19,351 | $8.80 | $170.3K | 4,004,920 |
| Apr 14, 2021↗ | KANE MATTHEW R. | President and CEO | Sell | 9,741 | $8.67 | $84.5K | 1,964,800 |
| Apr 12, 2021↗ | KANE MATTHEW R. | President and CEO | Sell | 19,473 | $8.93 | $174.0K | 1,953,020 |
| Mar 22, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 9,665 | $11.08 | $107.1K | 3,981,240 |
| Mar 18, 2021↗ | JANTZ DEREK | Chief Scientific Officer | Sell | 19,326 | $11.44 | $221.2K | 3,969,400 |
| Mar 16, 2021↗ | KANE MATTHEW R. | President and CEO | Sell | 9,712 | $11.36 | $110.3K | 1,929,470 |
| Mar 12, 2021↗ | KANE MATTHEW R. | President and CEO | Sell | 19,421 | $11.58 | $225.0K | 1,917,670 |
DTIL Insiders
Similar Stocks to DTIL
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B